Moreover, NUSAP1 could be used to predict postoperative metastasis and recurrence in patients with cervical cancer, and a Wnt/β-catenin pathway inhibitorXAV-939 may serve as a potential tailored treatment for NUSAP1-ovexpressed cervical cancer patients. This evidence concerns the gene NUSAP1 and cervical cancer.